Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protara Therapeutics Inc. TARA

Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with rare and specialty diseases. The Protara team prioritizes creativity, diverse perspectives and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).


Recent & Breaking News (NDAQ:TARA)

Mid-Afternoon Market Update: Dow Falls 50 Points; Fossil Shares Slide After Disappointing Results

Benzinga.com  May 10, 2017

Mid-Morning Market Update: Markets Open Lower; NVIDIA Beats Q1 Estimates

Benzinga.com  May 10, 2017

Proteon Therapeutics Announces First Quarter 2017 Financial Results

GlobeNewswire May 10, 2017

Proteon Therapeutics Receives FDA Breakthrough Therapy Designation for Vonapanitase

GlobeNewswire May 10, 2017

Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial

GlobeNewswire May 2, 2017

Proteon Therapeutics to Present at the Deutsche Bank 42nd Annual Health Care Conference May 4th

GlobeNewswire May 1, 2017

Lifshitz & Miller LLP Announces Investigation of BRF S.A., Innoviva, Inc., Panera Bread Company, PRA Group, Inc., Proteon Therapeutics, Inc., tronc, Inc. and Vuzix Corporation

PR Newswire April 5, 2017

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Proteon Therapeutics, Inc.

Business Wire March 23, 2017

Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd

GlobeNewswire March 17, 2017

Mid-Morning Market Update: Markets Open Higher; Dollar General Beats Q4 Expectations

Benzinga.com  March 16, 2017

Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial

GlobeNewswire March 16, 2017

Proteon Therapeutics Announces Two Presentations at the American Society of Diagnostic and Interventional Nephrology Meeting  

GlobeNewswire February 6, 2017

Mid-Day Market Update: Vericel Surges On Awaited FDA Approval; Proteon Therapeutics Shares Drop

Benzinga.com  December 14, 2016

15 Biggest Mid-Day Losers For Tuesday

Benzinga.com  December 13, 2016

Stocks Hitting 52-Week Lows

Benzinga.com  December 13, 2016

Mid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Forecast

Benzinga.com  December 13, 2016

Proteon Therapeutics Announces Top-Line Data from Phase 3 PATENCY-1 Clinical Trial of Investigational Vonapanitase in Patients with CKD

GlobeNewswire December 13, 2016

Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee

GlobeNewswire November 10, 2016

Proteon Therapeutics to Participate in Two Upcoming Investor Conferences

GlobeNewswire November 9, 2016

Proteon Therapeutics Announces Third Quarter 2016 Financial Results

GlobeNewswire November 7, 2016